Management of patients following detection of unsuspected colon lesions by PET imaging

Clinical Gastroenterology and Hepatology

Volumn 9, Issue 12, 2011, Pages 1025-1032

  Lin, Michael ^a,b,d   Koo, Jenn Hian ^a,c,d   Abi Hanna, David ^a,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Department of Nuclear Medicine and PET ^*  (Australia)

^c LIVERPOOL HOSPITAL   (Australia)

^d South Western Sydney Colorectal Tumour Group   (Australia)

Author keywords

Colon Cancer; Colorectal; Metastasis; Polyp

Indexed keywords

FLUORODEOXYGLUCOSE;

CANCER DIAGNOSIS; COLON ADENOMA; COLON INJURY; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG UPTAKE; DYSPLASIA; HISTOPATHOLOGY; HUMAN; INCIDENTAL FINDING; LARGE INTESTINE; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW;

COLON; COLONIC NEOPLASMS; HUMANS; POSITRON-EMISSION TOMOGRAPHY;

EID: 82955247651     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.06.028     Document Type: Review

References (45)

1. Lin M., Ho Shon I., Lin P. Positron emission tomography: current status and future challenges. Intern Med J 2010, 40:19-29.
2. Lin M., Wong K., Ng W.L., et al. Positron emission tomography and colorectal cancer. Crit Rev Oncol/Hematol 2011, 77:30-47.
3. Cronin C.G., Moore M., Blake M.A. Positron emission tomography/computerized tomography for the gastroenterologist and hepatologist. Clin Gastroenterol Hepatol 2009, 7:20-26.
4. Antoch G., Saoudi N., Kuehl H., et al. Accuracy of whole-body dual modality fluorine-18-2-fluoro-2-deoxy-d-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004, 22:4357-4368.
5. Cohade C., Osman M., Leal J., et al. Direct comparison of 18F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 2003, 44:1797-1803.
6. Czernin J., Allen-Auerbach M., Schelbert H. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med 2007, 48(Suppl 1):78S-88S.
7. Tatlidil R., Jadvar H., Bading J.R., et al. Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology 2002, 224:783-787.
8. Metser U., Even-Sapir E. Increased 18F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT. Semin Nucl Med 2007, 37:206-222.
9. Kim S., Chung J.K., Kim B.T., et al. Relationship between gastrointestinal F-18-fluorodeoxyglucose accumulation and gastrointestinal symptoms in whole-body PET. Clin Positron Imaging 1999, 2:273-280.
10. Murphy R., Doerger K.M., Nathan M.A., et al. Pretreatment with diphenoxylate hydrochloride/atropine sulfate (Lomotil) does not decrease physiologic bowel FDG activity on PET/CT scans of the abdomen and pelvis. Mol Imaging Biol 2009, 11:114-117.
11. Soyka J.D., Strobel K., Veit-Haibach P., et al. Influence of bowel preparation before 18F-FDG PET/CT on physiologic 18F-FDG activity in the intestine. J Nucl Med 2010, 51:507-510.
12. Otsuka H., Graham M.M., Kubo A., et al. The effect of oral contrast on large bowel activity in FDG-PET/CT. Ann Nucl Med 2005, 19:101-108.
13. Antoch G., Kuehl H., Kanja J., et al. Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology 2004, 230:879-885.
14. Blake M.A., Setty B.N., Cronin C.G., et al. Evaluation of the effects of oral water and low-density barium sulphate suspension on bowel appearance on FDG-PET/CT. Eur Radiol 2010, 20:157-164.
15. Gontier E., Fourme E., Wartski M., et al. High and typical 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging 2008, 35:95-99.
16. Özülker T., Özülker F., Mert M., et al. Clearance of the high intestinal 18F-FDG uptake associated with metformin after stopping the drug. Eur J Nucl Med Mol Imaging 2010, 37:1011-1017.
17. Oh J.R., Song H.C., Chong A., et al. Impact of medication discontinuation on increased intestinal FDG accumulation in diabetic patients treated with metformin. AJR Am J Roentgenol 2010, 195:1404-1410.
18. Kamel E.M., Thumshirn M., Truninger K., et al. Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med 2004, 45:1804-1810.
19. Lee S.T., Tan T., Poon A.M., et al. Role of low-dose, noncontrast computed tomography from integrated positron emission tomography/computed tomography in evaluating incidental 2-deoxy-2-[F-18]fluoro-d-glucose-avid colon lesions. Mol Imaging Biol 2008, 10:48-53.
20. Lee J.C., Hartnett G.F., Hughes B.G., et al. The segmental distribution and clinical significance of colorectal fluorodeoxyglucose uptake incidentally detected on PET-CT. Nucl Med Commun 2009, 30:333-337.
21. Gutman F., Alberini J.-L., Wartski M., et al. Incidental colonic focal lesions detected by FDG PET/CT. AJR Am J Roentgenol 2005, 185:495-500.
22. Luboldt W., Volker T., Wiedemann B., et al. Detection of relevant colonic neoplasms with PET/CT: promising accuracy with minimal CT dose and a standardised PET cut-off. Eur Radiol 2010, 20:2274-2285.
23. Weston B.R., Iyer R.B., Qiao W., et al. Ability of integrated positron emission and computed tomography to detect significant colonic pathology: the experience of a tertiary cancer center. Cancer 2010, 116:1454-1461.
24. Kei P.L., Vikram R., Yeung H.W., et al. Incidental finding of focal FDG uptake in the bowel during PET/CT: CT features and correlation with histopathologic results. AJR Am J Roentgenol 2010, 194:W401-W406.
25. Israel O., Yefremov N., Bar-Shalom R., et al. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance. J Nucl Med 2005, 46:758-762.
26. Yasuda S., Ide M., Takagi S., et al. F-18 FDG uptake in colonic adenoma. Clin Nucl Med 1998, 23:99-100.
27. Yasuda S., Fujii H., Nakahara T., et al. 18F-FDG PET in detection of colonic adenomas. J Nucl Med 2001, 42:989-992.
28. Van Kouwen M.C., Nagengast F.M., Jansen J.B., et al. 2-(18F)-fluoro-2-deoxy-d-glucose positron emission tomography detects clinical relevant adenomas of the colon: a prospective study. J Clin Oncol 2005, 23:3713-3717.
29. Nakajo M., Jinnouchi S., Tashiro Y., et al. Effect of clinicopathologic factors on visibility of colorectal polyps with FDG PET. AJR Am J Roentgenol 2009, 192:754-760.
30. Hemandas A.K., Robson N.K., Hickish T., et al. Colorectal tubulovillous adenomas identified on fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography scans. Colorectal Dis 2008, 10:386-389.
31. Ravizza D., Bartolomei M., Santoro L., et al. Positron emission tomography for the detection of colorectal adenomas. Dig Liver Dis 2010, 42:185-190.
32. Tsai S.C., Jeng L.B., Yeh J.J., et al. Findings of 2-fluoro-2-deoxy-D:-glucose positron emission tomography in hemorrhoids. Abdom Imaging 2010 Dec 9, [Epub ahead of print].
33. Abdel-Nabi H., Doerr R.J., Lamonica D.M., et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998, 206:755-760.
34. Minamimoto R., Senda M., Uno K., et al. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey. Ann Nucl Med 2007, 21:481-498.
35. Are C., Hsu J.F., Ghossein R.A., et al. Histological aggressiveness of fluorodeoxyglucose positron-emission tomogram (FDG-PET)-detected incidental thyroid carcinomas. Ann Surg Oncol 2007, 14:3210-3215.
36. Söreide K., Janssen E.A., Söiland H., et al. Microsatellite instability in colorectal cancer. Br J Surg 2006, 93:395-406.
37. Grgic A., Yüksel Y., Gröschel A., et al. Risk stratification of solitary pulmonary nodules by means of PET using 18F-fluorodeoxyglucose and SUV quantification. Eur J Nucl Med Mol Imaging 2010, 37:1087-1094.
38. Vivekanandarajah S., Lin M., Koo J.H., et al. Significance of incidental focal colonic uptake on FDG PET-CT and correlation with colonoscopy and histopathology. Australian Gastroenterology Week 2010.
39. Lieberman D. Colonoscopy: as good as gold?. Ann Intern Med 2004, 141:401-403.
40. Pickhardt P.J., Nugent P.A., Mysliwiec P.A. Location of adenomas missed by optical colonoscopy. Ann Intern Med 2004, 141:401-403.
41. Cotton P.B., Durkalski V.L., Pineau B.C., et al. Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. JAMA 2004, 291:1713-1719.
42. Rehani B., Chasen R.M., Dowdy Y., et al. Advanced adenoma diagnosis with FDG PET in a visibly normal mucosa: a case report. J Med Case Rep 2007, 1:99.
43. Mainenti P.P., Salvatore B., D'Antonio D., et al. PET/CT colonography in patients with colorectal polyps: a feasibility study. Eur J Nucl Med Mol Imaging 2007, 34:1594-1603.
44. Nagata K., Ota Y., Okawa T., et al. PET/CT colonography for the preoperative evaluation of the colon proximal to the obstructive colorectal cancer. Dis Colon Rectum 2008, 51:882-890.
45. Even-Sapir E., Lerman H., Gutman M., et al. The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT. Eur J Nucl Med Mol Imaging 2006, 33:541-552.